Ajax Therapeutics Appoints Srdan “Serge” Verstovsek, MD, PhD, to Scientific Advisory Board
Retrieved on:
Tuesday, December 6, 2022
Oncology, Health, Health Technology, Research, Science, Pharmaceutical, Biotechnology, Therapy, Pancreatic serous cystadenoma, Srđan, MD, Doctor of Philosophy, Drug discovery, Society, Research, MPN, Patient, Translational research, Section, International Work Group for Indigenous Affairs, MD Anderson Cancer Center, MSK, Ajax, Memorial Sloan Kettering Cancer Center, Myeloproliferative neoplasm, Division, Executive Committee, School of Dental Medicine, University of Zagreb, Committee, JAK2, American Society for Clinical Investigation, University, Computational chemistry, SAB, Pharmaceutical industry, Primary myelofibrosis, Leukemia
Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop novel small molecules for myeloproliferative neoplasms (MPNs), today announced the appointment of Srdan Serge Verstovsek, MD, PhD, to the Companys Scientific Advisory Board (SAB).
Key Points:
- Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop novel small molecules for myeloproliferative neoplasms (MPNs), today announced the appointment of Srdan Serge Verstovsek, MD, PhD, to the Companys Scientific Advisory Board (SAB).
- I am pleased to be joining the Ajax SAB at this exciting stage of the companys development, said Dr. Verstovsek.
- Ajax Therapeutics, Inc. is pursuing uniquely selective approaches to develop novel first-in-class therapeutics for myeloproliferative neoplasms (MPNs), including Myelofibrosis.
- NOTE: Dr. Ross Levine serves on the board of directors of, has provided advisory services for, and has equity interests in Ajax Therapeutics.